Optimizing the time of doxil injection to increase the drug retention in transplanted murine mammary tumors

International Journal of Nanomedicine

Volumn 5, Issue 1, 2010, Pages 221-229

  You, Shaojin ^a   Zuo, Lian ^a   Li, Wei ^a  

^a ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

Breast cancer therapy; Doxil; Menstrual cycle; Mouse mammary tumor; Progesterone

Indexed keywords

CXCL16 CHEMOKINE; DOXORUBICIN; FLT3 LIGAND; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PROGESTERONE; TUMOR NECROSIS FACTOR RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER TISSUE; CONTROLLED STUDY; DIESTRUS; DOSE TIME EFFECT RELATION; DRUG RETENTION; DRUG TISSUE LEVEL; ESTRUS; ESTRUS CYCLE; FEMALE; HORMONE ACTION; IN VITRO STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; PROGESTERONE BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION;

MURINAE; MUS;

EID: 77951191918     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/ijn.s8488     Document Type: Article

References (26)

1. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46: 6387-6392.
2. Sledge GW Jr, Miller KD. Exploiting the hallmarks of cancer: the future conquest of breast cancer. Eur J Cancer. 2003;39:1668-1675.
3. Wu J, Akaike T, Maeda H. Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 1998;58:159-165.
4. Lamprecht A, Ubrich N, Yamamoto H, et al. Biodegradable nanoparticles for targeted drug delivery in treatment of inflammatory bowel disease. J Pharmacol Exp Ther. 2001;299:775-781.
5. You S, Li W. Administration of nanodrugs in proper menstrual stage for maximal drug retention in breast cancer. Med Hypotheses. 2008;71: 141-147.
6. You S, Li W, Kobayashi M, et al. Creation of a stable mammary tumor cell line that maintains fertility-cycle tumor biology of the parent tumor. In Vitro Cell Dev Biol Anim. 2004;40:187-195.
7. Wood PA, Bove K, You S, et al. Cancer growth and spread are saltatory and phase-locked to the reproductive cycle through mediators of angiogenesis. Mol Cancer Ther. 2005;4:1065-1075.
8. Chu AC, Tsang SY, Lo EH, et al. Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells. Life Sci. 2001;70:591-601.
9. Lo EH, Ooi VE, Fung KP. Circumvention of multidrug resistance and reduction of cardiotoxicity of doxorubicin in vivo by coupling it with low density lipoprotein. Life Sci. 2002;72:677-687.
10. Charrois GJ, Allen TM. Rate of biodistribution of STEALTH liposomes to tumor and skin: influence of liposome diameter and implications for toxicity and therapeutic activity. Biochim Biophys Acta. 2003;1609:102-108.
11. Ford CE, Ekstrom EJ, Andersson T. Wnt-5a signaling restores tamoxifen sensitivity in estrogen receptor-negative breast cancer cells. Proc Natl Acad Sci USA. 2009;106:3919-3924.
12. Bergman MD, Schachter BS, Karelus K, et al. Up-regulation of the uterine estrogen receptor and its messenger ribonucleic acid during the mouse estrous cycle: the role of estradiol. Endocrinology. 1992;130:1923-1930.
13. Michael SD. Plasma prolactin and progesterone during the estrous cycle in the mouse. Proc Soc Exp Biol Med. 1976;153:254-257.
14. Rivera E. Liposomal anthracyclines in metastatic breast cancer: clinical update. Oncologist. 2003;8(Suppl 2):3-9.
15. Wahl AF, Donaldson KL, Mixan BJ, et al. Selective tumor sensitization to taxanes with the mAb-drug conjugate cBR96-doxorubicin. Int J Cancer. 2001;93:590-600.
16. Sinha BK, Katki AG, Batist G, et al. Differential formation of hydroxyl radicals by adriamycin in sensitive and resistant MCF-7 human breast tumor cells: implications for the mechanism of action. Biochemistry. 1987;26:3776-3781.
17. Bachur NR, Yu F, Johnson R, et al. Helicase inhibition by anthracycline anticancer agents. Mol Pharmacol. 1992;41:993-998.
18. Crespi MD, Ivanier SE, Genovese J, et al. Mitoxantrone affects topoisomerase activities in human breast cancer cells. Biochem Biophys Res Commun. 1986;136:521-528.
19. Hortobagyi GN, Buzdar AU, Marcus CE, et al. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986;(1):105-109.
20. Muggia FM. Clinical efficacy and prospects for use of pegylated liposomal doxorubicin in the treatment of ovarian and breast cancers. Drugs. 1997;54(Suppl 4):22-29.
21. Harmey JH, Bucana CD, Lu W, et al. Lipopolysaccharide-induced metastatic growth is associated with increased angiogenesis, vascular permeability and tumor cell invasion. Int J Cancer. 2002;101: 415-422.
22. Pidgeon GP, Harmey JH, Kay E, et al. The role of endotoxin/lipopolysaccharide in surgically induced tumour growth in a murine model of metastatic disease. Br J Cancer. 1999;81:1311-1317.
23. DuPre SA, Redelman D, Hunter KW Jr. The mouse mammary carcinoma 4T1: characterization of the cellular landscape of primary tumours and metastatic tumour foci. Int J Exp Pathol. 2007;88: 351-360.
24. Tohyama M, Sayama K, Komatsuzawa H, et al. CXCL16 is a novel mediator of the innate immunity of epidermal keratinocytes. Int Immunol. 2007;19:1095-1102.
25. Jablonska E. Release of soluble IL-6 receptor (IL-6sR) in comparison with release of soluble TNF receptors (sTNF-Rs) by PMNs and WBC derived from breast cancer patients. Cancer Lett. 1997;119:79-85.
26. Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol. 1997;17:70-77.